Nemtabrutinib (MK-1026, formerly ARQ 531) is a small molecule drug that works as a reversible

Bruton's tyrosine kinase Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the ''BTK'' gene in humans. BTK plays a crucial role in B cell development. Structure BTK contains five di ...

(BTK) inhibitor; unlike other BTK inhibitors it also works against some mutated forms of BTK. Merck paid $2.7 billion to acquire the company ArQule and the drug, which is being investigated as a cancer treatment.

References

Tyrosine kinase inhibitors Small-molecule drugs Phenol ethers Chloroarenes Benzaldehydes Pyrrolopyridines {{pharma-stub